ETF Managers Group launched an exchange-traded fund tracking companies focused on testing and treatments of infectious diseases.
The ETFMG Treatments, Testing and Advancements ETF, which started trading Thursday under the ticker GERM, gives access to both established biotechnology companies and “unsung heroes,” the firm said in a statement.
The fund tracks an index whose biggest holding is Moderna Inc., a company that’s seen its stock price more than triple this year on news of its progress in developing a vaccine.
As global coronavirus cases exceed 8.3 million, companies, health authorities, drug regulators and research institutes are working around the clock to come up with the world’s first effective vaccine for COVID-19. Concern over a second wave of the pandemic threatens recent efforts to relax restrictions and revive businesses after months of lockdowns.
“Everyone is thinking about treatments and vaccines,” said Sam Masucci, chief executive officer and founder of ETF Managers Group. “It touches them very personally. We tried to develop a product of all the companies at the forefront that will hopefully get us back to a more normalized life.”
The fund has a 0.68% expense ratio.
Earlier this year, Pacer Financial filed for a BioThreat ETF (VIRS), which is focused on companies combating biological threats to human health.
This kind of thematic fund is effectively “a trifecta bet” -- meaning the issuer has to get the theme, stocks and valuations right, according to Ben Johnson, director of global ETF research at Morningstar Inc.
Raymond James lures a $125M Merrill Lynch advisor in Charlotte while a Stifel pair breaks away to go independent in Southern Oregon
Pave Finance, DPL Financial Partners and Gottfried & Somberg also add senior leaders as RIAs and wealthtech firms deepen their benches
What the feud between “twin” index funds teaches thematic investors
RIAs flag AI risk in Form ADV more often than they admit using AI
Fake advisors, fake platforms, fake crypto - all on a six-month timer
Advisors are broadening the conversation beyond savings to help clients prepare for the realities of longer lives
Growing wealth, evolving priorities, and untapped opportunities are reshaping how women approach long-term investing.